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Palliative thoracic radiother-
apy is a cornerstone of any radiation 
oncology practice; older estimates 
from the United Kingdom suggest 
that 10% to 25% of a typical radia-
tion oncologist’s practice deals with 
lung-related issues, with a high pro-
portion of these palliative in nature.1 
A meta-analysis and guideline-based 
recommendations indicate that higher 
doses of palliative radiotherapy (such 
as 30 Gy in 10 fractions) translate to 
a modest benefit in overall survival 
when compared with lower biological 
effective dose regimens.2,3 Although it 
is difficult to retrospectively analyze 
the decision making in cases where 
lower doses of radiotherapy were 
used in our study, we do note that 
approximately half of patients (48%) 
received at least 20 Gy. From a prac-
tical point of view, a careful balance 
must be struck between the urgency 
of treatment and the ability to deliver 
higher doses of radiotherapy safely. 
Common palliative dose fractionation 
schemes (such as 8, 20, or 30 Gy in 1, 
5, and 10 fractions, respectively) can 
be planned and delivered on the same 
day as consultation. Conversely, any 
benefit in local control derived from 
higher doses, using intensity-modu-
lated radiotherapy or image-guided 
radiotherapy approaches, may be miti-
gated by delays incurred in a lengthier 
treatment-planning process.
Severe malignant airway obstruc-
tion can present dramatically and result 
in acute dyspnea and respiratory col-
lapse. Often these patients are urgently 
intubated and only afterward questions 
surrounding best management, includ-
ing a reasonable duration of trialing 
mechanical ventilation arise. We con-
sidered abstracting ventilation data, but 
ventilation strategies often changed dur-
ing treatment and were heterogenous. As 
with any intervention where the primary 
goal is palliation, assuring that functional 
status is improved by the intervention is 
paramount. Although we did not directly 
abstract quality of life or performance 
status data, the fact that approximately 
all extubated patients were discharged 
home, with some receiving chemother-
apy thereafter, can be considered surro-
gates of their improved functional status.
Although a randomized con-
trol trial to demonstrate the efficacy 
of radiotherapy over best supportive 
care in this patient population would 
be ideal, given these patients’ grave 
clinical situation and the suggestion 
that radiotherapy could be of benefit, 
it would be difficult to establish equi-
poise to run such a trial. Going for-
ward, we propose that institutions using 
radiotherapy in this setting develop 
guidelines with input from oncologists, 
intensivists, and allied health profes-
sionals. Just as important as identifying 
endpoints relevant to each multidisci-
plinary stakeholder, a guideline would 
set standards and policies to improve 
patient safety during transportation 
and minimize the time away from the 
intensive care unit. Although data from 
such an initiative would be intriguing, 
in the interim we would encourage oth-
ers to report their experience in using 
radiotherapy in this clinical setting or 
to discuss obstacles that currently pre-
vent them from doing so.
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To the Editor:
A 50-year-old asian man with a 
remote history of light smoking (half 
a pack per day × 4 years) presented 
to the orthopedic clinic with several 
months of progressively worsening 
right hip pain. A radiograph showed 
a lytic lesion in the right acetabu-
lum with soft-tissue involvement. 
Computed topography (CT)-guided 
biopsy revealed a moderately differ-
entiated adenocarcinoma, positive 
for TTF-1 and CK7 and negative for 
CK20 by immunohistochemistry. CT 
scan revealed a 10 mm irregular nodule 
in the apex of the left lung with hilar 
and mediastinal lymphadenopathy. 
The patient was diagnosed with meta-
static lung adenocarcinoma and staged 
as IVB. EGFR mutation  analysis 
was performed using  massively 
parallel sequencing using the Ion 
AmpliSeq Cancer Hotspot Panel v2 
(Life Technologies, Carlsbad, CA). 
A compound heterozygous mutation 
in exon 19 (c.2240T>C, p.L747S and 
c.2246_2260de15, p.A750_K754del) 
was identified (Fig. 1) and the result 
was confirmed by Sanger sequenc-
ing (Fig. 2). The two mutations were 
also found to be allelic as shown in 
Figure 1. Given the positive family his-
tory of lung cancer (father; no detailed 
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information available), EGFR mutation 
analysis was performed on the patient’s 
peripheral blood to rule out a germline 
mutation. No mutation was found. 
The patient was treated with Erlotinib, 
150 mg/d, in conjunction with pal-
liative radiation therapy directed to his 
right acetabulum. He developed non-
itching rashes on his nose and forehead 
and had loose stools, but otherwise 
tolerated the therapy. Follow-up chest 
CT after 2 months of Erlotinib showed 
interval decrease in the size of the lung 
nodule (Fig. 3), but slight increase in 
the size of a mediastinal lymph node. 
At 6-month follow-up, CT showed no 
interval tumor growth and radiograph 
showed improvement of the hip lesion. 
The patient had almost no hip pain, his 
energy level had increased, and he was 
able to go back to work full time.
Compound mutations comprise 
up to 14% of mutations identified in the 
tyrosine kinase domain (exons 18–21) 
of the EGFR gene.1 More than one-
third of the compound mutations found 
before therapy involve one of five amino 
FIGURE 2. Identification of EGFR exon 19 compound mutation by Sanger sequencing. Exons18-21 of the EGFR gene was 
polymerase chain reaction amplified and Sanger sequencing was performed. The hollow arrow indicates the c.2240T>C point 
mutation and the solid arrow marks the beginning of the15 base-pair deletion (c.2246_2260de15).
FIGURE 1. Identification of EGFR exon 19 compound mutation by massively parallel sequencing. Genomic DNA was extracted 
from formalin-fixed, paraffin-embedded tissue. EGFR mutation analysis was performed using the Ion AmpliSeq Cancer Hotspot 
Panel v2 (Life Technologies, Carlsbad, CA) at our molecular pathology laboratory. The hollow arrow indicates point mutation 
and the solid arrow indicates the region of the15 base-pair deletion.
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countries and several Asian ethnic 
groups. Vietnamese patients had the 
highest incidence of EGFR mutations, 
whereas Indian patients had the lowest 
while about half of Filipino patients 
harbored EGFR mutations.1 In addi-
tion, general epidemiology parameters 
were comprehensively collected from 
all seven countries including detailed 
smoking status.1 We have previously 
published that Vietnamese-American 
females had the highest percentages 
(65.5%) of never smokers among the 
the six Asian-American subgroups 
analyzed, whereas Japanese-American 
female NSCLC patients had the lowest 
proportion (19.3%) of never smokers 
and about half of Filipino-American 
female NSCLC patients were never-
smokers.2 Besides activating EGFR 
mutations, others targetable driver 
mutations such as rearrangement 
in ALK, ROS1, and RET are also 
found primarily in never-smokers. 
Therefore, would Professor Yang and 
his colleagues be able to provide the 
breakdown by smoking status among 
patients within each individual coun-
try and further breakdown of smoking 
status by sex within each of the seven 
countries.
Sai-Hong Ignatius Ou, MD, PhD
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Cancer Center
Irvine, CA 
acids: E709, G719, S768, T790, and 
L858.2 Exon 19 deletions are less fre-
quently found in compound mutations in 
untreated patients.3 The p.L747S muta-
tion is also rare with only seven cases 
being reported in the COSMIC database 
(http://cancer.sanger.ac.uk/cancerge-
nome/projects/cosmic). The compound 
p.L747S and p.A750_K754del mutation 
was only reported in one case in the litera-
ture, in a 73-year-old asian woman with 
unknown smoking status or therapy infor-
mation.2 Exon 19 deletions are known to 
be associated with sensitivity to tyrosine 
kinase inhibitor (TKI) and tumors harbor-
ing p.L747S mutation are TKI resistant.4 
We are reporting for the first time the 
Erlotinib response in a TKI-naive patient 
with a compound TKI-resistant and sen-
sitive mutation. The patient is currently 
in remission and still receiving Erlotinib 
therapy. It should be noted that cells car-
rying p.L747S mutation may become 
predominate after initial TKI response 
because of clonal selection of tumor cells 
carrying this p.L747S-resistant mutation.
Gagan Mathur, MD
Deqin Ma, MD, PhD
Department of Pathology, 
University of Iowa Hospitals and 
Clinics, Iowa City, IA. 
ACKNOWLEDGMENT
The authors thank Dr. Michael 
Gailey for critically reviewing this 
manuscript.
A B
FIGURE 3. Computed Tomography 
images of the initial presentation (A) and 
2 months post-Erlotinib treatment (B) of 
the lung nodule.
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I congratulate Professor Yang 
and his colleagues in successfully 
performed a multinational large-scale 
molecular epidemiology in the fre-
quency of activating EGFR mutations 
in treatment-naïve advanced adeno-
carcinoma of the lung in seven Asian 
Copyright © 2014 by the International Association 
for the Study of Lung Cancer
ISSN: 1556-0864/14/0907-0e57
